TTOO News and Press, T2 Biosystems Inc. From 02/13/23

LEXINGTON, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) today announced that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents) and warrants to purchase shares of its common stock. All of the securities ...

LEXINGTON, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced positive results upon completion of the U.S. clinical evaluation for the T2Biothreat™ Pan...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips In order for a free market to operate, investors must be willing to participate in both sides of the transaction, which brings us to the topic of the stocks to short this week. If you’re feeling optimistic about the pess...

LEXINGTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it has advanced to the Phase 2 accelerator in the U.S. Department of Health and Human Services (&...

T2 Biosystems ( NASDAQ: TTOO ) reported Q4 revenue of $5.5M, beating consensus of $5.47M, as per preliminary results. Q4 Product revenue was $2.2M while research contribution revenue amounted to $3.3M. The company's full year 2022 total revenue was $22.3M ( consensus ...

LEXINGTON, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the fourth quarter and full year 2022. ...

T2 Biosystems ( NASDAQ: TTOO ) said Wednesday its innovative technology contract with healthcare performance improvement firm Vizient has been extended through March 31, 2024 . Vizient members will continue to have access to broader exposure and contracted pricing for the T2Dx Ins...

LEXINGTON, Mass., Dec. 28, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its Innovative Technology contract with Vizient, Inc., the largest member-driven health car...

Summary Bionano Genomics, Inc. is an engaging company operating in the genome mapping space. The company generated $7.2m of revenues from 217 installed bases in Q322. Performance of genetic testing developers, e.g., Illumina and PacBio, in 2022 has been poor. Bionano is making b...

LEXINGTON, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the publication of a peer-reviewed article published by Oxford University Press on behalf of the ...